...MB07133 ; 60% of any net proceeds from any disposition of Metabasis' equity interest in PeriCor Therapeutics Inc....

...and commercialize IV acadesine from PeriCor under a 2007 deal (see BioCentury, July 23, 2007). PeriCor Therapeutics Inc....

...SGP will receive an exclusive worldwide license to develop and commercialize PeriCor's IV acadesine. The adenosine...
...ischemia/reperfusion injury. Financial terms were not disclosed. The deal is expected to close this quarter. PeriCor Therapeutics Inc....

...coverage and penetration. Additionally, the direct thrombin inhibitor retained its activity by binding to thrombin. PeriCor Therapeutics Inc....

...77% vs. placebo. Data were presented at the American College of Cardiology meeting in Atlanta. PeriCor Therapeutics Inc....